MET and neoplasm: Recent analysis of previously unreported results has shown that crizotinib produced either disease stabilization or tumor response in patients with NSCLC and high MET amplification, suggesting that crizotinib may be a potential agent for the treatment of MET-amplified NSCLC [76].